Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + Carfilzomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02332850Phase 1Completed
- Start
- Jan 2015
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms). Primary endpoints: Dose-Limiting Toxicities, Maximum Tolerated Dose and 1 more. Started Jan 2015; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02332850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02332850.